WO2005121343A1 - Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes - Google Patents
Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes Download PDFInfo
- Publication number
- WO2005121343A1 WO2005121343A1 PCT/CN2004/001321 CN2004001321W WO2005121343A1 WO 2005121343 A1 WO2005121343 A1 WO 2005121343A1 CN 2004001321 W CN2004001321 W CN 2004001321W WO 2005121343 A1 WO2005121343 A1 WO 2005121343A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adenovirus
- sequence
- gene
- recombinant
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- blocking sequences can block any RNA polymerase-mediated gene transcription, such as the early poly (A) terminal sequence of SV40; as encoded in the adenovirus E3 region Adenoviruses with deleted sequences of 10.4K, 14.5K and 14.7K.
- 525-811 hTERT promoter sequence and ligation sequence modified by genetic engineering technology
- the adenovirus sequence includes E4 and the right arm.
- the genomic sequence of the recombinant KH-900 is similar to sequence 3, except that the hTERT promoter is wild-type and has no subtraction changes. See sequence 1 and sequence 2. There is no polyadenylation nucleotide signal sequence between the viral gene packaging region and the hTERT promoter.
- the genomic sequence of the recombinant KH-902 is similar to that of KH-901, but the immunoregulatory gene GM-CSF has been changed from a secreted type in KH-901 to a membrane-bound type.
- the genomic sequence of the recombinant KH-903 is similar to that of KH-901, except that the sequences encoding 10.4K, 14.5K, and 14.7K in the E3 region have been deleted.
- the deleted sequences are related to adenoviral bases 29804 to 30857. These three genes encode proteins that suppress immune responses, especially tumor necrosis factor-mediated immune responses. Therefore, deleting oncolytic adenoviruses from these three genes may induce a stronger anti-tumor immune response.
- Recombinant KH-905 is an immunomodulatory protein based on recombinant KH-904 GM-CSF changed from secreted to membrane-bound.
- the genome of the recombinant KH-906 is based on KH-901, and the ribosome entry site (IRES) is used to replace the EIB promoter [Li et al. (2001) Cancer Research 62: 1 Zhang J et al. (2002) Cancer Research 62: 3743-3750].
- IRS ribosome entry site
- the invention also includes the preparation of the promoter.
- Two primers are designed and synthesized according to the hTERT promoter sequence in FIG. 1:
- the human hTERT promoter was amplified by PCR using the activated human genomic RNA as a template.
- the reaction component is: First cycle: 94. C denaturation for 5 minutes, 81 ° C annealing for 1 minute, 72. C extended for 2 minutes; subsequent cycles: 93. C denaturation for 1 minute, 68. C annealing for one minute, 72 ° C extension for 2 minutes, a total of 35 cycles.
- the PCR product thus obtained was analyzed by agarose gel electrophoresis, and the hTERT promoter fragment was recovered. After sequencing analysis, the obtained promoter fragments were the same as those published ( Figure 1).
- This DNA was then cloned into the pUC19 vector, and the hTERT promoter sequence was changed to the sequence shown in FIG. 2 by the site-directed mutation method (Strategene site-directed induction method).
- telomere activity in the hTERT promoter there is no common conserved sequence like "TATA", but it contains two "CACGTG” E-boxes and four "GC” -rich Sp-I binding regions. These conserved sequences are the key to regulate the expression of telomerase activity in the hTERT promoter through C-Myc / Max complex and Sp-I [Cong et al. (1999) Human Moleular Genetics 8 (1): 137-142; Kyo et al. (2000) Nucleic Acids Research 28 (3): 669-677]. Many experiments show that Myc plays an important role in the process of cell proliferation and cell cycle. The hTERT promoter affects the transcription and expression of telomerase.
- the E2F-1 promoter can transcribe linked genes in tumor cells lacking the pRb / E2F / pl 6-channel pathway, the E2F-1 promoter is widely used in gene therapy, especially for the construction of replicative adenoviruses [Parr et al. (1997) Nature Medicine 3 (10): 1145-1149; Jakubczak et al. (2003) Cancer Research 63: 1490-1499; Bristol et al. (2003) Molecular Therapy 7 (6): 755- 763].
- a transcription termination signal is installed after the end of the adenovirus (ITR) and the packaging site, and before the exogenous promoter (such as the hTERT promoter).
- ITR adenovirus
- hTERT promoter adenovirus
- These blocking sequences can block Cut off any RNA polymerase-mediated gene transcription.
- SV40 early poly (A) terminal sequence poly (A) terminal sequence.
- the recombinant of the present invention is equipped with an immunoregulatory gene.
- the cytokine GM-CSF is installed.
- the recombinant of the present invention is also installed with GM-CSF, but is not limited to using only GM-CSF, and may be other cytokines. But GM-CSF is considered to be the most active immunomodulatory factor (Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90: 3539-3543).
- GM-CSF granulocytes
- monocytes month package white cell monocytes
- giant fine ⁇ 1 month package macrophage
- fine dendritic packet dendritic cells
- GM-CSF can also promote tissue infiltration of immune cells and B cell differentiation. Therefore, in the past few years, scientists have used recombinant GM-CSF protein and chemotherapy drugs to treat tumor patients together. At the same time, many Two tumor cells using GM-CSF-expressing tumor cells are being tested in clinical trials [Armitage Jo (1998) Blood 92: 4491-4508; Mach et al.
- GM-CSF membrane-bound cytokine
- mbGM-CSF membrane-bound cytokine
- the idea of using membrane-bound GM-CSF in oncolytic adenoviruses is based on published work. Research work has shown that membrane-bound GM-CSF can enhance the effect on dendritic cells and produce a stronger conditioning effect on dendritic cells than secreted GM-CSF [Soo Hoo et al. (1999 ) Journal oflmmundogy 169: 7343-7349; Yei et al. (2002) Gene Therapy 6: 1302-1311]. The concept of recombinant membrane-engineered drugs and the expression of membrane-bound cytokine GM-CSF in oncolytic viruses have not been reported.
- the invention also includes a method for preparing the recombinant of the invention, which method comprises the following steps: a) preparation of the left arm of an adenovirus containing the hTERT promoter sequence;
- the recombinant of the present invention can be specifically obtained by the following method:
- the recombinant virus is obtained by homologous recombination in eukaryotic cells.
- PXC.1 purchased by Microbix in Canada
- the hTERT promoter sequence was recorded to obtain pKH-901a.
- pBHGE3 purchased by Microbix in Canada
- adenovirus's right arm was used to replace the gpl9k gene in the E3 region with the immunomodulatory gene GM-CSF in a similar manner to obtain PKH-901b.
- PKH-901a and PKH-901b together transform HeLa cells by homologous recombination Get KH-901.
- other recombinant adenoviruses including KH-900, KH-902, KH-903, KH-904, KH-905 and KH-906 were constructed by similar methods.
- the recombinant can be obtained by homologous recombination in any direct cell or prokaryotic cell.
- the PCR amplification method was used to add the endonuclease sites Sspl and PinAI (Agel) at the 362th to 551th bases of pXC.l, respectively.
- the hTERT promoter was amplified from the human gene bank by PCR, and together with the polyadenylate sequence, the two end fragments were taken out by PCR in vitro to form a piece of DNA. Add the endonuclease sites Sspl and PinAI to both ends of this DNA.
- the digested DNA fragment was ligated with multiple similarly digested pXC.l to transform E. coli strain DH5-alpha cells (Invitrogen, USA). 'After transformation, 10 plaques were selected, cultured in an incubator for 24 hours, DNA was extracted, identified by enzyme digestion analysis, and the resulting sequence was named PKH-901a.
- the constructed recombinant vectors pKH-901a and pKH-901b were transfected into HeLa cells to make them homologous.
- the two purified plasmid DNAs were linearized with Clal, and then transformed into HeLa cells via lipofectin [USA Invitrogen]. After 10 days of transformation, the cells were scraped off, lyophilized three times, and 1.00 microliters were taken on HeLa cells.
- Virus spot detection After 8 days, virus spots began to be seen under the low freezing point gel. Six virus plaques were selected and seeded into pre-seeded HeLa cells. After 4 to 6 days, the lysed cell fluid was collected and stored at low temperature.
- Wild-type adenovirus Ad5 defective adenovirus dl312 [E1A deletion], recombinants KH-900 and KH-901 were used to infect human nascent humans.
- hFKs-E6 human papilloma virus type 16, HPV-16
- hFKs-E6 transformed HPV16-E6 cells have much higher telomerase activity than their parental cells [Horikawa et al. (2001) Journal Virology 75 (9): 4467-4472].
- KH-900 and KH-901 were used to infect (1 infection unit per cell) 293 cells and bone marrow stem cells, and then the cell viability was measured. As shown in Figure 8, KH-900 and KH-901 kill 293 cells. Equivalent. KH-901 has almost zero killing power on bone marrow stem cells, but KH-900 has certain killing effect on bone marrow stem cells.
- the prostate tumor cell line LNcap cells were used to establish a tumor model in mice, and 6 million cells were inoculated subcutaneously. After 4 weeks, the tumors were seen growing to about 200 cubic microliters. At this time, a total of three doses were given (Day 1, Day 5, and Day 9), and each dose was administered with 3x10 '° virus particles. Tumor volume was then measured twice a week. The resulting tumor growth data are shown in Figure 10.
- Fig. 10 It can be seen from Fig. 10 that the tumors treated with the preparation containing no virus grew quickly, and the tumor volume of the control group after 48 days was 1,200 (1200%) when the drug was started.
- tumor growth has been inhibited to a certain extent.
- tumors treated with KH-901 remain the same as baseline, and tumors treated with KH-904 reduce tumor volume to 15% of the initial dose. (15%).
- the growth of tumors treated with Addll520 was affected to a certain extent, and its volume was 850 percent (850%) at the beginning of administration.
- GM-CSF expression in the tumor was also recorded. Fourteen days after administration, the expression of GM-CSF was not detected in the blood of animals treated with Addll520 and KH-907, while in the blood of animals buried at KH901 and KH-904, 2.322 ⁇ g / ml and 2.776 ⁇ g / ml of GM-CSF. This result indicates that GM-CSF in the recombinant adenovirus is not only expressed in tumor cells in vitro, but also expressed at higher levels in tumors on animals.
- the installed tumor regulatory elements are active in more than 90% of tumors, that is, in most tumor cells, key genes of these adenoviruses can be expressed so that the virus can replicate and reproduce, thereby killing tumor cells. So these recombinant oncolytic replicating adenoviruses will be very extensive, such as head and neck cancer, lung cancer, rectal cancer, prostate cancer, bladder cancer, stomach cancer, liver cancer, etc.
- Ad5 receptor protein (CAR) Adenovirus blood group 5 (Ad5) receptor protein (CAR) is not expressed or expressed at a low level in a large part of tumor cells, so it is often seen that Ad5 cannot infect tumor cells well.
- Ad35 Adenovirus blood group 35 (Ad35) receptor binding site and sequence to the Ad5 gene In the group, the efficiency of infecting most tumor cells can be greatly improved. Both in vitro and in vivo tests have proven the superiority of recombinants constructed in this design (see experimental examples).
- Adenovirus sequences include E1A, E1B, E2, etc .;
- Sequence 5 The fibrin gene sequence of adenovirus blood group 35 in the genome of recombinant KH-904 (Fiber knob: Ad5 / 35). Brief description of the drawings:
- FIG. 1 The hTERT promoter with higher tumor cell specificity and transcription activity modified by modified mutations.
- E2F-1 E2F transcription factor binding site.
- Figure 6 Activity of hTERT promoter: comparison of wild-type promoter (telo) and modified promoter (Mtelo).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04797352.4A EP1767642B1 (en) | 2004-06-07 | 2004-11-19 | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof |
US11/628,760 US7951585B2 (en) | 2004-06-07 | 2004-11-19 | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof |
CA2568995A CA2568995C (en) | 2004-06-07 | 2004-11-19 | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof |
PL04797352T PL1767642T3 (pl) | 2004-06-07 | 2004-11-19 | Konstrukcja onkolitycznego rekombinanta adenowirusa swoiście eksprymującego czynnik immunomodulujący GM-CSF w komórkach nowotworowych i jego zastosowania |
JP2007526164A JP4874247B2 (ja) | 2004-06-07 | 2004-11-19 | 腫瘍溶解性アデノウイルス組換え体、特に、腫瘍において免疫調節因子gm−csfを発現する組換え体の構築およびその利用 |
BRPI0418805A BRPI0418805B8 (pt) | 2004-06-07 | 2004-11-19 | construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos |
DK04797352.4T DK1767642T3 (da) | 2004-06-07 | 2004-11-19 | Konstruktion af onkolytiske adenovirus rekombinant specifikt udtrykkende immunmodulatorisk faktor gm-csf i tumorceller og anvendelser deraf |
ES04797352.4T ES2466415T3 (es) | 2004-06-07 | 2004-11-19 | Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410046237.X | 2004-06-07 | ||
CNB200410046237XA CN100361710C (zh) | 2004-06-07 | 2004-06-07 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121343A1 true WO2005121343A1 (fr) | 2005-12-22 |
Family
ID=35503069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/001321 WO2005121343A1 (fr) | 2004-06-07 | 2004-11-19 | Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes |
Country Status (12)
Country | Link |
---|---|
US (1) | US7951585B2 (zh) |
EP (1) | EP1767642B1 (zh) |
JP (1) | JP4874247B2 (zh) |
CN (1) | CN100361710C (zh) |
BR (1) | BRPI0418805B8 (zh) |
CA (1) | CA2568995C (zh) |
DK (1) | DK1767642T3 (zh) |
ES (1) | ES2466415T3 (zh) |
PL (1) | PL1767642T3 (zh) |
PT (1) | PT1767642E (zh) |
RU (1) | RU2361611C2 (zh) |
WO (1) | WO2005121343A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006079169A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes |
WO2013027427A1 (ja) * | 2011-08-23 | 2013-02-28 | 独立行政法人医薬基盤研究所 | 制限増殖型アデノウイルス |
US9624476B2 (en) | 2011-08-23 | 2017-04-18 | National Institute Of Biomedical Innovation | Conditionally replicating adenovirus |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
HUE053612T2 (hu) | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Intravitreális bevitelre alkalmas VEGF-antagonista készítmények |
JP2008048621A (ja) * | 2006-08-22 | 2008-03-06 | Chiba Prefecture | キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬 |
CN101391104B (zh) * | 2007-09-21 | 2010-10-06 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的新用途 |
WO2012038607A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
CA2865642C (en) * | 2012-03-14 | 2021-10-26 | Salk Institute For Biological Studies | Adenoviral tumor diagnostics |
US9017672B2 (en) | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
CA2940123C (en) * | 2013-03-24 | 2023-10-10 | Oisin Biotechnologies | Systems and methods for the targeted production of a therapeutic protein within a target cell |
EP2987858B1 (en) | 2013-04-17 | 2019-08-14 | Kyushu University, National University Corporation | Gene-modified coxsackievirus |
CN114457044A (zh) | 2013-10-25 | 2022-05-10 | 普西奥克瑟斯医疗有限公司 | 武装有异源基因的溶瘤腺病毒 |
WO2015080631A1 (en) * | 2013-11-27 | 2015-06-04 | Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" | Improved expression vector for toll-like receptor and agonist and use for treating cancer |
RS60105B1 (sr) | 2015-04-30 | 2020-05-29 | Psioxus Therapeutics Ltd | Onkološki adenovirus kodiran proteinom b7 |
WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
US11525146B2 (en) | 2017-01-09 | 2022-12-13 | Oisin Biotechnologies, Inc. | Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof |
CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
KR102167934B1 (ko) * | 2017-12-13 | 2020-10-20 | 진메디신 주식회사 | 재조합 아데노바이러스 및 이를 포함하는 줄기세포 |
WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
KR20210093303A (ko) | 2018-11-21 | 2021-07-27 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
WO2020166727A1 (ja) * | 2019-02-12 | 2020-08-20 | 国立大学法人大阪大学 | ヒト35型アデノウイルスを基板とした腫瘍溶解性ウイルス |
JP7381604B2 (ja) | 2019-04-29 | 2023-11-15 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 癌を治療するための多価pd-l1結合化合物 |
WO2021194180A1 (ko) * | 2020-03-23 | 2021-09-30 | ㈜큐리진 | 이중 특이적 핵산분자를 포함한 항암 바이러스의 구조 |
RU2753742C1 (ru) * | 2020-10-16 | 2021-08-24 | Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор |
CN115029325A (zh) * | 2021-03-08 | 2022-09-09 | 南京惟亚德生物医药有限公司 | 一种重组溶瘤腺病毒及其应用 |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009399A2 (en) | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
WO1999046371A2 (en) | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
WO2002067861A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Oncolytic adenoviral vectors |
CN1381582A (zh) | 2001-04-13 | 2002-11-27 | 上海华康生物技术有限公司 | 靶向性、高表达人粒细胞巨噬细胞集 落刺激因子的重组腺病毒及其制法和用途 |
CN1382218A (zh) | 1999-11-15 | 2002-11-27 | 昂尼克斯药物公司 | 溶瘤腺病毒 |
WO2003013555A1 (en) | 2001-08-08 | 2003-02-20 | Board Of Regents, The University Of Texas System | Method for amplifying expression from a cell specific promoter |
US6627190B2 (en) | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
WO2005112541A2 (es) | 2004-05-20 | 2005-12-01 | Proyecto De Biomedicina Cima, S.L. | Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
CN1298451A (zh) * | 1998-04-24 | 2001-06-06 | 昂尼克斯药物公司 | 用于治疗疾病的腺病毒载体 |
GB9916851D0 (en) * | 1999-07-20 | 1999-09-22 | Univ Wales Bangor | Manipulation of particles in liquid media |
AU9434801A (en) * | 2000-08-10 | 2002-02-18 | Crucell Holland Bv | Gene delivery vectors with cell type specificity for primary human chondrocytes |
US6905678B2 (en) * | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
CN1195056C (zh) * | 2001-07-12 | 2005-03-30 | 钱其军 | 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法 |
US20030099616A1 (en) * | 2001-07-25 | 2003-05-29 | Irving John M. | Dual specificity tumor killing vectors driven by the telomerase promoter |
JP3867968B2 (ja) * | 2002-07-08 | 2007-01-17 | 関西ティー・エル・オー株式会社 | 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス |
CN1259106C (zh) * | 2002-12-23 | 2006-06-14 | 中国科学院上海生命科学研究院 | 一种抗癌靶向基因病毒药物的制备方法 |
-
2004
- 2004-06-07 CN CNB200410046237XA patent/CN100361710C/zh not_active Expired - Lifetime
- 2004-11-19 US US11/628,760 patent/US7951585B2/en active Active
- 2004-11-19 BR BRPI0418805A patent/BRPI0418805B8/pt active IP Right Grant
- 2004-11-19 PT PT47973524T patent/PT1767642E/pt unknown
- 2004-11-19 EP EP04797352.4A patent/EP1767642B1/en active Active
- 2004-11-19 ES ES04797352.4T patent/ES2466415T3/es active Active
- 2004-11-19 CA CA2568995A patent/CA2568995C/en active Active
- 2004-11-19 DK DK04797352.4T patent/DK1767642T3/da active
- 2004-11-19 PL PL04797352T patent/PL1767642T3/pl unknown
- 2004-11-19 RU RU2006146665/13A patent/RU2361611C2/ru active
- 2004-11-19 JP JP2007526164A patent/JP4874247B2/ja active Active
- 2004-11-19 WO PCT/CN2004/001321 patent/WO2005121343A1/zh active Search and Examination
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009399A2 (en) | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
WO1999046371A2 (en) | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
US6627190B2 (en) | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
CN1382218A (zh) | 1999-11-15 | 2002-11-27 | 昂尼克斯药物公司 | 溶瘤腺病毒 |
US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
WO2002067861A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Oncolytic adenoviral vectors |
CN1381582A (zh) | 2001-04-13 | 2002-11-27 | 上海华康生物技术有限公司 | 靶向性、高表达人粒细胞巨噬细胞集 落刺激因子的重组腺病毒及其制法和用途 |
WO2003013555A1 (en) | 2001-08-08 | 2003-02-20 | Board Of Regents, The University Of Texas System | Method for amplifying expression from a cell specific promoter |
WO2005112541A2 (es) | 2004-05-20 | 2005-12-01 | Proyecto De Biomedicina Cima, S.L. | Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales |
Non-Patent Citations (27)
Title |
---|
ARMITAGE, BLOOD, vol. 92, 1998, pages 4491 - 4508 |
BRISTOL ET AL., MOLECULE THERAPY, vol. 7, no. 6, 2003, pages 755 - 763 |
CHIOCCA EA, NATURE REVIEW CANCER, vol. 2, 2002, pages 938 - 950 |
CONG ET AL., HUMAN MOLECULAR GENETICS, vol. 8, no. 1, 1999, pages 137 - 142 |
DRANOFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3539 - 3543 |
GILBOA, NATURE REVIEWS CANCER, vol. 4, 2004, pages 401 - 411 |
GREEN ET AL., INT. J. CANCER, vol. 104, 2003, pages 104 - 112 |
HAHN WC, CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 1203 - 1205 |
HORIKAWA ET AL., JOURNAL OF VIROLOGY, vol. 75, no. 9, 2001, pages 4467 - 4472 |
HUANG ET AL., CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 1439 - 1445 |
JAKUBCZAK ET AL., CANCER RESEARCH, vol. 63, 2003, pages 1490 - 1499 |
KAWASHIMA ET AL., CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 285 - 292 |
KYO ET AL., NUCLEIC ACIDS RESEARCH, vol. 28, no. 3, 2000, pages 669 - 677 |
LI ET AL., CANCER RESEARCH, vol. 61, 2001, pages 6428 - 6436 |
LI ET AL., CANCER RESEARCH, vol. 62, 2001 |
LI ET AL., CANCER RESEARCH, vol. 62, 2001, pages 2667 - 2674 |
MACH ET AL., CANCER RESEARCH, vol. 60, 2000, pages 3239 - 3246 |
MASUTOMI ET AL., CELL, vol. 114, 2003, pages 241 - 253 |
MCCORMICK F, NATURE REVIEW CANCER, vol. 1, 2001, pages 130 - 141 |
MULLEN, TANABE, THE ONCOLOGIST, vol. 7, 2002, pages 106 - 119 |
PARR ET AL., NATURE MEDICINE, vol. 3, no. 10, 1997, pages 1145 - 1149 |
See also references of EP1767642A4 * |
SHAYAKHMETOV ET AL., CANCER RESEARCH, vol. 62, 2002, pages 1063 - 1068 |
SIRENA ET AL., JOURNAL OF VIROLOGY, vol. 78, no. 9, 2004, pages 4454 - 4462 |
SOO HOO ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 1999, pages 7343 - 7349 |
YEI ET AL., GENE THERAPY, vol. 6, 2002, pages 1302 - 1311 |
ZHANG ET AL., CANCER RESEARCH, vol. 62, 2002, pages 3743 - 3750 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006079169A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes |
WO2013027427A1 (ja) * | 2011-08-23 | 2013-02-28 | 独立行政法人医薬基盤研究所 | 制限増殖型アデノウイルス |
CN103857795A (zh) * | 2011-08-23 | 2014-06-11 | 独立行政法人医药基盘研究所 | 限制增殖型腺病毒 |
US9624476B2 (en) | 2011-08-23 | 2017-04-18 | National Institute Of Biomedical Innovation | Conditionally replicating adenovirus |
Also Published As
Publication number | Publication date |
---|---|
CA2568995C (en) | 2012-02-21 |
RU2361611C2 (ru) | 2009-07-20 |
EP1767642A4 (en) | 2008-06-25 |
PT1767642E (pt) | 2014-06-03 |
BRPI0418805B1 (pt) | 2021-01-26 |
JP2008501349A (ja) | 2008-01-24 |
US20100047208A1 (en) | 2010-02-25 |
CA2568995A1 (en) | 2005-12-22 |
JP4874247B2 (ja) | 2012-02-15 |
EP1767642A1 (en) | 2007-03-28 |
BRPI0418805A (pt) | 2007-10-16 |
EP1767642B1 (en) | 2014-04-23 |
DK1767642T3 (da) | 2014-05-26 |
CN100361710C (zh) | 2008-01-16 |
RU2006146665A (ru) | 2008-07-20 |
ES2466415T3 (es) | 2014-06-10 |
CA2568995E (en) | 2005-12-22 |
BRPI0418805B8 (pt) | 2021-05-25 |
CN1706955A (zh) | 2005-12-14 |
PL1767642T3 (pl) | 2014-08-29 |
US7951585B2 (en) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005121343A1 (fr) | Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes | |
AU696495B2 (en) | Adenoviral vectors of animal origin and use in gene therapy | |
US20080118470A1 (en) | Oncolytic adenoviral vectors encoding GM-CSF | |
JP4376454B2 (ja) | アデノウイルスベクター及び相同組換えイベントの低減方法 | |
JP4386971B2 (ja) | スプライシング配列を含んでなる組換えアデノウイルスベクター | |
AU2002346084B2 (en) | Viral mutants that selectively replicate in targeted human cancer cells | |
US20060257370A1 (en) | Adenoviral vectors for treating diseases | |
AU772963B2 (en) | Adenoviral vectors for treating disease | |
AU2002346084A1 (en) | Viral mutants that selectively replicate in targeted human cancer cells | |
ES2239841T3 (es) | Vectores adenovirales quimericos. | |
WO2006125381A1 (fr) | Virus du gene de ciblage tumoral zd55-il-24, son procede de construction et son application | |
WO2022012028A1 (zh) | 构建体、溶瘤病毒及其应用 | |
CA2373352A1 (en) | Adenoviral vectors for treating disease | |
CN113774031B (zh) | 一种复制型人腺病毒及其应用 | |
RU2194755C2 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pAd5-f, НЕСУЩАЯ ФРАГМЕНТ ГЕНОМА АДЕНОВИРУСА 5 ТИПА С ДЕЛЕЦИЕЙ В ГЕНЕ E1B-55K, И ШТАММ МУТАНТНОГО АДЕНОВИРУСА Ade12, ОБЛАДАЮЩИЙ СЕЛЕКТИВНОЙ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ | |
AU2005209653B2 (en) | Adenoviral vectors for treating disease | |
ES2367240T3 (es) | Vectores adenovíricos para le tratamiento de enfermedades. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2568995 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007526164 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11628760 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7442/DELNP/2006 Country of ref document: IN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004797352 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006146665 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004797352 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: PI0418805 Country of ref document: BR |